New drug combo shows promise for rare nerve tumors
NCT ID NCT03433183
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested two drugs, selumetinib and sirolimus, in 21 people with advanced malignant peripheral nerve sheath tumors (MPNST), a rare cancer often linked to neurofibromatosis type 1. The goal was to see if the combination could shrink or stabilize tumors. The study measured how many patients had their disease controlled for at least four treatment cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Selumetinib and sirolimus
- What this could lead to
- If successful, this combination could offer a new treatment option to slow or stop tumor growth in patients with advanced malignant peripheral nerve sheath tumors.
- What could go wrong
- This is a small, early-phase trial with only 21 participants. The results may not apply to all patients, and the combination may cause side effects without improving survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
National Cancer Institute
Bethesda, Maryland, 20892, United States
-
Washington University
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Light-Activated cream could slow growth of NF1 skin tumors
- Antioxidant drug shows promise for kids with NF1
- New drug targets rare nerve tumors in people with specific gene loss
- Could a common supplement help kids with NF1 learn and move better?
- New drug combo aims to tame rare childhood leukemia
- New stem cell transplant aims to cut dangerous side effects in blood cancer patients